8.18
+3.94%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Atara Biotherapeutics
From its filings with the US Securities and Exchange Commission
Atara Biotherapeutics is based in Thousand Oaks, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ATRA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $120.8m and net income of $32.7m. At that date it held total assets of $20.2m and shareholders' equity of −$38.5m.
Atara Biotherapeutics is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune disease. Tab-cel®(tabelecleucel), has received marketing authorization approval under the proprietary name Ebvallo by the European Commission (EC) for commercial sale and use in the European Economic Area (EEA), by the Medicines and Healthcare products Regulatory Agency (MHRA) for commercial sale and use in the United Kingdom (UK) and by Swissmedic for commercial sale and use in Switzerland. We partnered with Pierre Fabre Medicament (Pierre Fabre) for commercialization of tab-cel in Europe and potential commercialization, if approved, worldwide, including in the U.S. Tab-cel is currently in Phase 3 development in the U.S. for patients with EBV- associated post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases.
Our pipeline also includes ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX signaling domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform, and ATA3431, an allogeneic dual CAR T immunotherapy targeting both CD19 and CD20 for B-cell malignancies; and a potential next generation EBV vaccine which is differentiated from earlier EBV vaccine efforts that solely focused on B cell responses to EBV.
Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Oct 2014
- Employees
- 14
- Website
- atarabio.com ↗
- Head office
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Gregory CiongoliNon-Executive Chairman of the Board
- Mr. Anhco NguyenPresident, Chief Executive Officer, Director, since 2023$1.6m
- Dr. Carol GallagherLead Independent Director$191,552
- Mr. Matthew FustIndependent Director$169,100
- Mr. William HeidenIndependent Director$170,762
- Mr. James HuangIndependent Director
- Mr. Nachi SubramanianIndependent Director
- Mr. Amber DaughertySenior Director, Strategy and Operations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 34
- Social
- 99
- Governance
- 45
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is a clinical stage biotechnology firm focused on developing novel therapeutics for cancer, autoimmune, and viral diseases.
- Headquartered in South San Francisco, California with a focus on severe and life-threatening diseases.
- Operates through the development and commercialization of therapeutics, specifically allogeneic T-cell therapies.
Weaknesses
- Source description states 437 employees, but company data lists 14 employees, indicating a significant discrepancy.
- Company is clinical stage, meaning it has not yet commercialized any products.
- Reliance on multiple product candidates in various stages of clinical trials without commercial success.
Opportunities
- Potential for growth in the biotechnology sector with increasing focus on novel therapies for severe diseases.
- Expansion of T-cell therapy applications for various diseases including cancer and autoimmune conditions.
- Opportunity to leverage clinical trial successes to advance product candidates like ATA129 and ATA520.
Threats
- High risk associated with clinical stage development without commercialized products.
- Discrepancy in employee count may indicate operational inefficiencies or mismanagement.
- Competition in the biotechnology sector for similar therapeutic approaches.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.